title: [Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
abstract: OBJECTIVE
  Hepatic arterial infusion (HAI) chemotherapy for hepatic metastasis from colorectal cancer has higher response rates compared with systemic chemotherapy, but can not control extrahepatic lesions. So the combination chemotherapy with HAI plus systemic chemotherapy is expected. This study ascertained the efficacy and toxicity of combined chemotherapy with HAI plus systemic CPT-11.
  
  
  METHODS
  Seventeen patients were treated with concurrent HAI 5-FU 700-800 mg/m(2) on day 1, 8, 15, 22 and systemic CPT-11 70-80 mg/m(2) on day 1 and 15. Treatment was repeated every 28 days.
  
  
  RESULTS
  The objective response rate for all patients was 76.5% (13 of 17 patients), and time to progression was about 10 months. Median survival time was about 20 months, and no difference was seen in the survival of patients without extrahepatic lesions and patients with extrahepatic lesions (21 months vs 18.5 months; p=0.5). The incidence of new extrahepatic metastasis in patients without extrahepatic lesions was 9% (1 of 11 patients). Grade 3 or 4 neutropenia was found in only 2 patients (11.8%).
  
  
  CONCLUSIONS
  Combination therapy with HAI 5-FU plus systemic CPT-11 may be safely administered to patients with colorectal cancer. The incidence of new extrahepatic metastases was low in comparison with reports of HAI monotherapy.
authors.affiliation: Dept. of Internal Medicine and Medical Oncology, Misawa City Hospital.
authors.forename: Kohei
authors.initials: K
authors.lastname: Shitara
authors.forename: Masaki
authors.initials: M
authors.lastname: Munakata
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kudo
authors.forename: Masaharu
authors.initials: M
authors.lastname: Kasai
authors.forename: Osamu
authors.initials: O
authors.lastname: Muto
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Okada
authors.forename: Sumako
authors.initials: S
authors.lastname: Mitobe
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ishiguro
authors.forename: Hirotake
authors.initials: H
authors.lastname: Sakuraba
authors.forename: Isao
authors.initials: I
authors.lastname: Ikami
authors.forename: Yuh
authors.initials: Y
authors.lastname: Sakata
mesh_terms: D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D015996:Survival Rate
chemical_list: D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin